Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 107

1.

Candidate gene DNA methylation associations with breast cancer characteristics and tumor progression.

Kresovich JK, Gann PH, Erdal S, Chen HY, Argos M, Rauscher GH.

Epigenomics. 2018 Apr 1;10(4):367-378. doi: 10.2217/epi-2017-0119. Epub 2018 Mar 12.

PMID:
29528252
2.

Computer vision detects subtle histological effects of dutasteride on benign prostate.

Sethi A, Sha L, Kumar N, Macias V, Deaton RJ, Gann PH.

BJU Int. 2018 Jul;122(1):143-151. doi: 10.1111/bju.14172. Epub 2018 Mar 25.

PMID:
29461667
3.

Correlations of SELENOF and SELENOP genotypes with serum selenium levels and prostate cancer.

Ekoue DN, Ansong E, Liu L, Macias V, Deaton R, Lacher C, Picklo M, Nonn L, Gann PH, Kajdacsy-Balla A, Prins GS, Freeman VL, Diamond AM.

Prostate. 2018 Mar;78(4):279-288. doi: 10.1002/pros.23471. Epub 2018 Jan 5.

4.

Arylsulfatase B is reduced in prostate cancer recurrences.

Feferman L, Deaton R, Bhattacharyya S, Xie H, Gann PH, Melamed J, Tobacman JK.

Cancer Biomark. 2017 Dec 12;21(1):229-234. doi: 10.3233/CBM-170680.

PMID:
29081414
5.

BRCA1 protein expression and subcellular localization in primary breast cancer: Automated digital microscopy analysis of tissue microarrays.

Mahmoud AM, Macias V, Al-Alem U, Deaton RJ, Kadjaksy-Balla A, Gann PH, Rauscher GH.

PLoS One. 2017 Sep 1;12(9):e0184385. doi: 10.1371/journal.pone.0184385. eCollection 2017.

6.

Prostatic compensation of the vitamin D axis in African American men.

Richards Z, Batai K, Farhat R, Shah E, Makowski A, Gann PH, Kittles R, Nonn L.

JCI Insight. 2017 Jan 26;2(2):e91054. doi: 10.1172/jci.insight.91054.

7.

microRNAs and DICER1 are regulated by 1,25-dihydroxyvitamin D in prostate stroma.

Dambal S, Giangreco AA, Acosta AM, Fairchild A, Richards Z, Deaton R, Wagner D, Vieth R, Gann PH, Kajdacsy-Balla A, Van der Kwast T, Nonn L.

J Steroid Biochem Mol Biol. 2017 Mar;167:192-202. doi: 10.1016/j.jsbmb.2017.01.004. Epub 2017 Jan 12.

8.

Epidermal growth factor prevents APOE4 and amyloid-beta-induced cognitive and cerebrovascular deficits in female mice.

Thomas R, Zuchowska P, Morris AW, Marottoli FM, Sunny S, Deaton R, Gann PH, Tai LM.

Acta Neuropathol Commun. 2016 Oct 27;4(1):111.

9.

Baseline Prostate-Specific Antigen Levels in Midlife Predict Lethal Prostate Cancer.

Preston MA, Batista JL, Wilson KM, Carlsson SV, Gerke T, Sjoberg DD, Dahl DM, Sesso HD, Feldman AS, Gann PH, Kibel AS, Vickers AJ, Mucci LA.

J Clin Oncol. 2016 Aug 10;34(23):2705-11. doi: 10.1200/JCO.2016.66.7527. Epub 2016 Jun 13.

10.

Empirical comparison of color normalization methods for epithelial-stromal classification in H and E images.

Sethi A, Sha L, Vahadane AR, Deaton RJ, Kumar N, Macias V, Gann PH.

J Pathol Inform. 2016 Apr 11;7:17. doi: 10.4103/2153-3539.179984. eCollection 2016.

11.

Retinoid and carotenoid status in serum and liver among patients at high-risk for liver cancer.

Kataria Y, Deaton RJ, Enk E, Jin M, Petrauskaite M, Dong L, Goldenberg JR, Cotler SJ, Jensen DM, van Breemen RB, Gann PH.

BMC Gastroenterol. 2016 Feb 29;16:30. doi: 10.1186/s12876-016-0432-5.

12.

Associations Between Serum Vitamin D and Adverse Pathology in Men Undergoing Radical Prostatectomy.

Nyame YA, Murphy AB, Bowen DK, Jordan G, Batai K, Dixon M, Hollowell CM, Kielb S, Meeks JJ, Gann PH, Macias V, Kajdacsy-Balla A, Catalona WJ, Kittles R.

J Clin Oncol. 2016 Apr 20;34(12):1345-9. doi: 10.1200/JCO.2015.65.1463. Epub 2016 Feb 22.

13.

Nipple Aspirate Fluid Hormone Concentrations and Breast Cancer Risk.

Chatterton RT, Heinz RE, Fought AJ, Ivancic D, Shappell C, Allu S, Gapstur S, Scholtens DM, Gann PH, Khan SA.

Horm Cancer. 2016 Apr;7(2):127-36. doi: 10.1007/s12672-016-0252-7. Epub 2016 Feb 22.

14.

High incidence of triple negative breast cancers following pregnancy and an associated gene expression signature.

Asztalos S, Pham TN, Gann PH, Hayes MK, Deaton R, Wiley EL, Emmadi R, Kajdacsy-Balla A, Banerji N, McDonald W, Khan SA, Tonetti DA.

Springerplus. 2015 Nov 19;4:710. doi: 10.1186/s40064-015-1512-7. eCollection 2015.

15.

A Phase II Randomized Trial of Lycopene-Rich Tomato Extract Among Men with High-Grade Prostatic Intraepithelial Neoplasia.

Gann PH, Deaton RJ, Rueter EE, van Breemen RB, Nonn L, Macias V, Han M, Ananthanarayanan V.

Nutr Cancer. 2015;67(7):1104-12. doi: 10.1080/01635581.2015.1075560.

16.

Evidence that selenium binding protein 1 is a tumor suppressor in prostate cancer.

Ansong E, Ying Q, Ekoue DN, Deaton R, Hall AR, Kajdacsy-Balla A, Yang W, Gann PH, Diamond AM.

PLoS One. 2015 May 18;10(5):e0127295. doi: 10.1371/journal.pone.0127295. eCollection 2015.

17.

Concerns about methods for determination of estrogens in body fluids.

Chatterton RT, Muzzio M, Gann PH.

Breast Cancer Res Treat. 2014 Dec;148(3):685. doi: 10.1007/s10549-014-3177-2. Epub 2014 Nov 11. No abstract available.

PMID:
25385178
18.

Dietary influences on tissue concentrations of phytanic acid and AMACR expression in the benign human prostate.

Kataria Y, Wright M, Deaton RJ, Rueter EE, Rybicki BA, Moser AB, Ananthanrayanan V, Gann PH.

Prostate. 2015 Feb;75(2):200-10. doi: 10.1002/pros.22905. Epub 2014 Oct 13.

19.

Methodological considerations in estrogen assays of breast fluid and breast tissue.

Chatterton RT, Muzzio M, Heinz R, Gann PH, Khan SA.

Steroids. 2015 Jul;99(Pt A):103-7. doi: 10.1016/j.steroids.2014.08.002. Epub 2014 Aug 24.

PMID:
25159105
20.

PTK6/BRK is expressed in the normal mammary gland and activated at the plasma membrane in breast tumors.

Peng M, Emmadi R, Wang Z, Wiley EL, Gann PH, Khan SA, Banerji N, McDonald W, Asztalos S, Pham TN, Tonetti DA, Tyner AL.

Oncotarget. 2014 Aug 15;5(15):6038-48.

21.

Serum phytanic and pristanic acid levels and prostate cancer risk in Finnish smokers.

Wright ME, Albanes D, Moser AB, Weinstein SJ, Snyder K, Männistö S, Gann PH.

Cancer Med. 2014 Dec;3(6):1562-9. doi: 10.1002/cam4.319. Epub 2014 Aug 16.

22.

Further evidence that prostate-specific antigen screening reduces prostate cancer mortality.

Stampfer MJ, Jahn JL, Gann PH.

J Natl Cancer Inst. 2014 Mar;106(3):dju026. doi: 10.1093/jnci/dju026. Epub 2014 Mar 7. No abstract available.

PMID:
24610908
23.

Nicotinamide phosphoribosyltransferase inhibitor is a novel therapeutic candidate in murine models of inflammatory lung injury.

Moreno-Vinasco L, Quijada H, Sammani S, Siegler J, Letsiou E, Deaton R, Saadat L, Zaidi RS, Messana J, Gann PH, Machado RF, Ma W, Camp SM, Wang T, Garcia JG.

Am J Respir Cell Mol Biol. 2014 Aug;51(2):223-8. doi: 10.1165/rcmb.2012-0519OC.

24.

Hormonal determinants of nipple aspirate fluid yield among breast cancer cases and screening controls.

Fought AJ, McGathey C, Scholtens DM, Heinz RE, Lowe R, Feeney YB, Lee O, Kmiecik TE, Wolfman JA, Clevenger CV, Gann PH, Gapstur S, Chatterton RT, Khan SA.

Cancer Epidemiol Biomarkers Prev. 2013 Dec;22(12):2277-84. doi: 10.1158/1055-9965.EPI-12-0434. Epub 2013 Sep 18.

25.

Development of a nuclear morphometric signature for prostate cancer risk in negative biopsies.

Gann PH, Deaton R, Amatya A, Mohnani M, Rueter EE, Yang Y, Ananthanarayanan V.

PLoS One. 2013 Jul 26;8(7):e69457. doi: 10.1371/journal.pone.0069457. Print 2013.

26.

The effects of selenium and the GPx-1 selenoprotein on the phosphorylation of H2AX.

Jerome-Morais A, Bera S, Rachidi W, Gann PH, Diamond AM.

Biochim Biophys Acta. 2013 Jun;1830(6):3399-406. doi: 10.1016/j.bbagen.2013.03.010. Epub 2013 Mar 18.

27.

Prediagnostic circulating sex hormones are not associated with mortality for men with prostate cancer.

Gershman B, Shui IM, Stampfer M, Platz EA, Gann PH, Sesso HL, DuPre N, Giovannucci E, Mucci LA.

Eur Urol. 2014 Apr;65(4):683-9. doi: 10.1016/j.eururo.2013.01.003. Epub 2013 Jan 11.

28.

Prostate specific antigen best practice statement: 2009 update.

Greene KL, Albertsen PC, Babaian RJ, Carter HB, Gann PH, Han M, Kuban DA, Sartor AO, Stanford JL, Zietman A, Carroll P; American Urological Association.

J Urol. 2013 Jan;189(1 Suppl):S2-S11. doi: 10.1016/j.juro.2012.11.014.

PMID:
23234625
29.

Estimated phytanic acid intake and prostate cancer risk: a prospective cohort study.

Wright ME, Bowen P, Virtamo J, Albanes D, Gann PH.

Int J Cancer. 2012 Sep 15;131(6):1396-406. doi: 10.1002/ijc.27372. Epub 2012 Jan 24.

30.

Associations between functional polymorphisms in antioxidant defense genes and urinary oxidative stress biomarkers in healthy, premenopausal women.

Al-Alem U, Gann PH, Dahl J, van Breemen RB, Mistry V, Lam PM, Evans MD, Van Horn L, Wright ME.

Genes Nutr. 2012 Apr;7(2):191-5. doi: 10.1007/s12263-011-0257-3. Epub 2011 Nov 9.

31.

Changes in the activity of the GPx-1 anti-oxidant selenoenzyme in mononuclear cells following imatinib treatment.

Terry EN, Gann PH, Molokie R, Deininger M, Diamond AM.

Leuk Res. 2011 Jun;35(6):831-3. doi: 10.1016/j.leukres.2011.01.007. Epub 2011 Feb 2.

32.

Subcellular localization of p27 and prostate cancer recurrence: automated digital microscopy analysis of tissue microarrays.

Ananthanarayanan V, Deaton RJ, Amatya A, Macias V, Luther E, Kajdacsy-Balla A, Gann PH.

Hum Pathol. 2011 Jun;42(6):873-81. doi: 10.1016/j.humpath.2010.10.006. Epub 2011 Feb 2.

33.

What is the true number needed to screen and treat to save a life with prostate-specific antigen testing?

Loeb S, Vonesh EF, Metter EJ, Carter HB, Gann PH, Catalona WJ.

J Clin Oncol. 2011 Feb 1;29(4):464-7. doi: 10.1200/JCO.2010.30.6373. Epub 2010 Dec 28.

34.

Prostate cancer: A closer look at the initial results from the REDUCE trial.

Gann PH.

Nat Rev Urol. 2010 Oct;7(10):535-7. doi: 10.1038/nrurol.2010.144. No abstract available.

PMID:
20930862
35.

Gene expression patterns in the human breast after pregnancy.

Asztalos S, Gann PH, Hayes MK, Nonn L, Beam CA, Dai Y, Wiley EL, Tonetti DA.

Cancer Prev Res (Phila). 2010 Mar;3(3):301-11. doi: 10.1158/1940-6207.CAPR-09-0069. Epub 2010 Feb 23.

36.

Risk factors for prostate cancer detection after a negative biopsy: a novel multivariable longitudinal approach.

Gann PH, Fought A, Deaton R, Catalona WJ, Vonesh E.

J Clin Oncol. 2010 Apr 1;28(10):1714-20. doi: 10.1200/JCO.2008.20.3422. Epub 2010 Feb 22.

37.

mRNA and micro-RNA expression analysis in laser-capture microdissected prostate biopsies: valuable tool for risk assessment and prevention trials.

Nonn L, Vaishnav A, Gallagher L, Gann PH.

Exp Mol Pathol. 2010 Feb;88(1):45-51. doi: 10.1016/j.yexmp.2009.10.005. Epub 2009 Oct 27.

38.

Prostate specific antigen best practice statement: 2009 update.

Greene KL, Albertsen PC, Babaian RJ, Carter HB, Gann PH, Han M, Kuban DA, Sartor AO, Stanford JL, Zietman A, Carroll P.

J Urol. 2009 Nov;182(5):2232-41. doi: 10.1016/j.juro.2009.07.093. Epub 2009 Sep 24.

PMID:
19781717
39.

Evidence for field cancerization of the prostate.

Nonn L, Ananthanarayanan V, Gann PH.

Prostate. 2009 Sep 15;69(13):1470-9. doi: 10.1002/pros.20983. Review.

40.

Randomized trials of antioxidant supplementation for cancer prevention: first bias, now chance--next, cause.

Gann PH.

JAMA. 2009 Jan 7;301(1):102-3. doi: 10.1001/jama.2008.863. Epub 2008 Dec 9. No abstract available.

PMID:
19066369
41.

Associations of serum carotenoid levels with serum insulin-like growth factor-i and insulin-like growth factor binding protein-3 levels in black men and white men.

Kim YL, Jacobs DR Jr, Gross MD, Bergan RC, Gann PH, Liu K, Gapstur SM.

Cancer Epidemiol Biomarkers Prev. 2007 Dec;16(12):2781-3. No abstract available.

42.

Soy isoflavone consumption is not associated with increased risk of advanced prostate cancer.

Bosland MC, Gann PH.

Cancer Epidemiol Biomarkers Prev. 2007 Oct;16(10):2169; author reply 2169-70. No abstract available.

43.

Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the Prostate Cancer Prevention Trial.

Cohen YC, Liu KS, Heyden NL, Carides AD, Anderson KM, Daifotis AG, Gann PH.

J Natl Cancer Inst. 2007 Sep 19;99(18):1366-74. Epub 2007 Sep 11.

PMID:
17848668
44.

Does active treatment improve survival in elderly men with localized prostate cancer?

Wright ME, Gann PH.

Nat Clin Pract Urol. 2007 Aug;4(8):420-1. Epub 2007 Jul 3. No abstract available.

PMID:
17609660
45.

Serum androgens and prostate cancer among 643 cases and 643 controls in the European Prospective Investigation into Cancer and Nutrition.

Travis RC, Key TJ, Allen NE, Appleby PN, Roddam AW, Rinaldi S, Egevad L, Gann PH, Rohrmann S, Linseisen J, Pischon T, Boeing H, Johnsen NF, Tjønneland A, Overvad K, Kiemeney L, Bueno-de-Mesquita HB, Bingham S, Khaw KT, Tumino R, Sieri S, Vineis P, Palli D, Quirós JR, Ardanaz E, Chirlaque MD, Larrañaga N, Gonzalez C, Sanchez MJ, Trichopoulou A, Bikou C, Trichopoulos D, Stattin P, Jenab M, Ferrari P, Slimani N, Riboli E, Kaaks R.

Int J Cancer. 2007 Sep 15;121(6):1331-8.

46.

Risk factors for prostate cancer.

Gann PH.

Rev Urol. 2002;4 Suppl 5:S3-S10.

47.
48.

Alteration of proliferation and apoptotic markers in normal and premalignant tissue associated with prostate cancer.

Ananthanarayanan V, Deaton RJ, Yang XJ, Pins MR, Gann PH.

BMC Cancer. 2006 Mar 17;6:73.

49.

Estrogen and progesterone levels in nipple aspirate fluid of healthy premenopausal women: relationship to steroid precursors and response proteins.

Gann PH, Geiger AS, Helenowski IB, Vonesh EF, Chatterton RT.

Cancer Epidemiol Biomarkers Prev. 2006 Jan;15(1):39-44.

50.

IGF-1, IGFBP-3, and nutritional factors in young black and white men: the CARDIA Male Hormone Study.

Colangelo LA, Chiu BC, Liu K, Kopp PA, Gann PH, Gapstur SM.

Nutr Cancer. 2005;53(1):57-64.

PMID:
16351507

Supplemental Content

Support Center